cenerimod
idorsia pharmaceuticals
['cenerimod']
#eular2023 #pos1147 primary endpoint for cenerimod (s1p1 modulator) phase 2 rct in #sle was not met after multiple testing. post-hoc analysis showed greater reduction in sri-4 and msledai in ifn-high vs ifn-low at 6mths. a biomarker to stratify response in phase 3 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling 🌏